I-Sorafenib Tosylate CAS 475207-59-1 Purity ≥99.0% (HPLC) API Factory High Quality
I-Commercial Supply Sorafenib Tosylate kanye Nezixhumanisi Ezihlobene:
I-Sorafenib Tosylate CAS: 475207-59-1
I-Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
| Igama Lekhemikhali | I-Sorafenib Tosylate |
| Omqondofana | I-Nexavar;4-[4-[3-[4-Chloro-3-(Trifluoromethyl)phenyl]ureido]phenoxy]-N-Methylpicolinamide 4-Methylbenzenesulfonate;4- [[4-Chloro-3-(Trifluoromethyl)phenyl]carbamamido]phenoxy]-N-Methyl-2-Pyridinecarboxamide 4-Methylbenzenesulfonate;I-BAY 43-9006 Tosylate |
| Inombolo ye-CAS | 475207-59-1 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
| I-Molecular Formula | I-C21H16ClF3N4O3.C7H8O3S |
| Isisindo samangqamuzana | 637.03 |
| I-Melting Point | 225.0 ukuze 230.0 ℃ |
| Kuyazwela | Izwela Umoya, Izwela Ukushisa |
| Ukuncibilika | I-Soluble in Water (<1 mg/ml) ku-25℃, i-DMSO (127 mg/ml) ku-25℃, ne-Ethanol (<1 mg/ml) ku-25℃ |
| Imibandela Yokuthumela | Indawo Epholile Neyomile (2~8℃), Vikela Ekukhanyeni |
| I-COA ne-MSDS | Iyatholakala |
| I-Shelf Life | Iminyaka emi-2 uma igcinwe kahle |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane | Imiphumela |
| Ukubukeka | Impushana Ephuzi Ekhanyayo noma Emhlophe | Iyahambisana |
| Ukuhlanzeka / Indlela Yokuhlaziya | ≥99.0% (HPLC) | 99.8% |
| I-Melting Point | 225.0~230.0℃ | Iyahambisana |
| Izinsimbi Ezisindayo | ≤10ppm | <10ppm |
| Ukulahlekelwa Ekumisweni | ≤0.50% | 0.12% |
| Izinsalela ekushiseni | ≤0.20% | 0.10% |
| Noma Ikuphi Ukungcola Okukodwa | ≤0.50% | Iyahambisana |
| Ukungcola Okuphelele | ≤0.50% | Iyahambisana |
| I-NMR Spectrum | Ivumelana Nesakhiwo | Iyahambisana |
| Izinga Lokuhlola | I-Enterprise Standard | Iyahambisana |
| Ukusetshenziswa | I-Sorafenib Tosylate (CAS: 475207-59-1) ekwelapheni i-RCC ne-HCC | |
Iphakheji:Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina esitsheni esivalwe ngci.Gcina endaweni epholile, eyomile (2~8℃) futhi enomoya omuhle kude nezinto ezingahambelani.Vikela ekukhanyeni nakumswakama.
Ukuthumela:Zilethe emhlabeni wonke ngendiza, yi-FedEx/DHL Express.Nikeza ukulethwa okusheshayo nokuthembekile.
Amakhodi Engozi 36/37/38 - Ukucasula amehlo, uhlelo lokuphefumula kanye nesikhumba.
Incazelo Yokuphepha S28 - Ngemva kokuthinta isikhumba, geza ngokushesha ngensipho eningi.
S26 - Uma uthintana namehlo, geza ngokushesha ngamanzi amaningi futhi ufune iseluleko sezokwelapha.
I-Sorafenib Tosylate (CAS: 475207-59-1) iwuhlobo olusha lwesidakamizwa esilwa nesimila esihloselwe izinto eziningi, sathuthukiswa yi-German Bayer Pharmaceuticals, futhi yabonisa umsebenzi wokulwa nesimila owandayo ekuhlolweni kwezilwane ngaphambi komtholampilo.I-Sorafenib itholakala kumaphilisi angu-200-mg ukuze iphathwe ngomlomo futhi isetshenziselwa ukwelapha i-RCC ne-HCC.I-Sorafenib Tosylate ingathinta kanyekanye amaseli wesimila kanye nemithambo yegazi yesimila.Inomphumela we-antitumor ophindwe kabili: ingavimba izindlela zokudluliselwa kwesignali yeseli exhunywe yi-RAF/MEK/ERK ukuze ivimbele ngokuqondile ukukhula kwe-tumor cell, kuyilapho ivimbela i-VEGF kanye ne-platelet derived growth factor (PDGF) receptors ukuvimbela ukwakheka kwegazi elisha lesimila. imikhumbi, ngaleyo ndlela ivimbele ngokungaqondile ukukhula kwamangqamuzana e-tumor.
I-Sorafenib Tosylate, igama lokuhweba i-Nexavar, yasungulwa okokuqala ngabakwa-Bayer Pharmaceuticals eJalimane.I-Sorafenib Tosylate iyi-multi-kinase inhibitor engasetshenziswa ukwelapha izifo ezinjengomdlavuza.Ngo-December 2005, yagunyazwa yi-US FDA njengomuthi womugqa wokuqala wokwelapha umdlavuza wezinso othuthukile.Ngo-Agasti 2009, yafakwa ohlwini ngokusemthethweni e-China ngemvume ye-State Food and Drug Administration.
I-Sorafenib Tosylate yi-tyrosine kinases (VEGFR ne-PDGFR) kanye ne-RAF/MEK/ERK cascade inhibitors, esebenza ngesikhathi esisodwa ku-Raf-1,wtBRAF ne-V599EBRAF, ne-IC50 ye-6 nM, 22 nM kanye ne-38 nM, ngokulandelana.
I-Sorafenib Tosylate ingavimbela ngesikhathi esisodwa izinhlobonhlobo ze-kinases ezikhona kuseli nangaphezulu kweseli, okuhlanganisa i-RAF kinase, i-vascular endothelial growth factor receptor-2 (VEGFR-2), i-vascular endothelial growth factor receptor-3 (VEGFR-3), iplatelet. -derived growth factor receptor-β (PDGFR-β), KIT kanye FLT-3.Kuyabonakala ukuthi i-sorafenib toluenesulfonate inemiphumela emibili elwa nesimila.Ngakolunye uhlangothi, ingavimbela ngokuqondile ukukhula kwesimila ngokuvimbela indlela yokubonisa i-RAF/MEK/ERK;ngakolunye uhlangothi, ingavimbela i-VEGFR ne-PDGFR.Futhi vimba ukwakheka kwe-tumor neovascularization, ukuvimbela ngokungaqondile ukukhula kwamaseli wesimila.I-Sorafenib Tosylate ingumuthi osebenza kahle kakhulu ekwelapheni umdlavuza wesibindi oqhubekayo ngokuphathwa ngendlela ehlelekile, futhi cishe izoba umuthi omusha ojwayelekile wokwelapha lesi sifo.
I-Sorafenib Tosylate kanye ngosuku yokulawulwa komlomo yokufakelwa kwesilwane somuntu ibonise imisebenzi eminingi elwa ne-tumor, kuhlanganise nomdlavuza wekoloni, umdlavuza we-cell non-small cell, umdlavuza webele, i-melanoma, umdlavuza we-pancreatic, i-leukemia kanye nomdlavuza we-ovarian kanye ne-mouse renal cell carcinoma. imodeli, imodeli ye-RENCA.
